drugset / Trial / NCT06612645
Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors
Phase 1
Recruiting
9 enrolled
Chulalongkorn University
King Chulalongkorn Memorial Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cells with IL-7Ra signal targeting B7H3 in children with solid tumors patients after complete standard treatments.
Timeline
- Start
- 2025-04-01
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B7H3-IL7Ra CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | B7H3-IL7Ra CAR-T cells | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | B7H3-IL7Ra CAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |